Zymeworks logo
Zymeworks
ZYME | NASDAQ
Chart Builder DCF Calculator
$26.45
+$0.21 (+0.80%)
At close: Nov 16, 2026, 4:00 PM ET
$26.45
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Zymeworks Company Profile

Company profile explained

Company Profile

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Key Executives

Name Position
Kenneth H. Galbraith Chairman of the Board, Chief Executive Officer & President
Mark Hollywood Executive VP & Chief Operating Officer
Bijal Desai Senior Vice President of Finance
Diana Papove Vice President of Corporate Communications
Kristin Stafford Executive VP & CFO
Laura O'Connor Senior VP & Chief Human Resources Officer
Lindsey Foulkes Senior Vice President of Corporate Development & Strategy
Paul Moore Chief Scientific Officer
Paul R. Schneider Executive VP & General Counsel
Sabeen Mekan Senior VP & Chief Medical Officer
Scott Platshon Executive VP & Chief Business Officer
Shrinal Inamdar Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Oct 26, 2026 ARS Filing
Oct 26, 2026 DEFA14A Filing
Oct 26, 2026 DEF 14A Filing
Oct 23, 2026 8-K Current Report
Oct 16, 2026 PRE 14A Filing
Oct 09, 2026 4 Filing
Sep 23, 2026 8-K Current Report
Aug 25, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
View All SEC Filings ➞
Zymeworks
Zymeworks logo
Country United States
IPO Date Apr 28, 2017
Industry Biotechnology
Sector Healthcare
Employees 231
CEO Kenneth H. Galbraith

Contact Details

108 Patriot Drive Middletown, Delaware 19709 United States

Stock Details

Ticker Symbol ZYME
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001937653
CUSIP Number 98985Y108
ISIN Number US98985Y1082
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.